Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Lymphoma, Non-Hodgkin 2Lymphoma 2Waldenstrom Macroglobulinemia 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neuroblastoma 1Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Leukemia, B-Cell 1Leukemia 1Hodgkin Disease 1Hematologic Diseases 1Ganglioneuroblastoma 1

Interventions

Lenalidomide 3Melphalan 2Granulocyte-Macrophage Colony-Stimulating Factor 2Dexamethasone 2Bortezomib 2sargramostim 1ixazomib 1fludarabine phosphate 1fludarabine 1Voriconazole 1Thalidomide 1Sugars 1Stem Cell Transplantation 1Platelet Transfusion 1Leukapheresis 1Fluconazole 1Cyclophosphamide 1Colony-Stimulating Factors 1Calcium Dobesilate 1Bone Marrow Transplantation 1Blood Specimen Collection 1B3(Fv)-PE38KDEL recombinant immunotoxin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Hematologic Diseases × Leukapheresis × Clear all
NCT02728102 2024-05-07

Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)

National Heart, Lung, and Blood Institute (NHLBI)

Phase 2 Completed
203 enrolled 25 charts
Plasma cell

Hematologic Diseases, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡